



Munich Re Group

Quarterly statement as at 31 March 2023


17 May 2023

Christoph Jurecka (CFO)



Quarterly statement as at 31 March 2023

Agenda





tampatra stock.adobe.com

01


Munich Re

Good start to the year with earnings above pro-rata guidance

Elevated result in prior-year quarter result due to lower major losses and FX


Net result

€m




Total technical result

€m




Net financial result

€m




Operating result

€m



Return on equity¹

%



Reinsurance (net result: €1,051m)

Strong investment result (RoI 3.8%¹) and sound operating performance in both segments; above-average major losses

Property-casualty: Combined ratio: 86.5% (77.0%) – major-loss ratio: 16.4% (11.1%), reserve releases²: –5.0% (–5.3%) – net result: €760m (€958m)

Life and health: Total technical result: €320m (€238m) – net result: €291m (€367m)

April renewals: Risk-adjusted price change: ~ +4.7%, premium change: +11.1%

ERGO (net result: €219m)

High contribution from P&C Germany; P&C international impacted by large losses; L/H Germany burdened by expenses

Life and Health Germany: Total technical result: €258m (€243m) – net result: €41m (€137m)








Property-casualty Germany: Combined ratio: 81.2% (106.3%) – net result: €166m (–€64m)

International: Combined ratio: 95.4% (88.7%) – net result: €12m (€84m)

Capital position


Equity

€m

Equity 31.12.2022	27,245	
Net result	1,271	
Changes		
Dividend	0	
Share buy-backs	-373	
Unrealised gains/losses	749	
Exchange rates	-281	
Other ¹	-428	
Equity 31.3.2023	28,182	

Capitalisation

€bn



Change in unrealised gains/losses

Investments	€ 1,923 m
Insurance contracts	-€ 1,174 m

Return on equity

Reinsurance	17.8%
ERGO	15.4%

Solvency II ratio


254%

Investments

Q1 2023


Investment portfolio¹

%



Government/Semi-government bonds ²	34 (34)	Alternative investments	15 (15)
Covered bonds/mortgage loans	15 (15)	Equities ³	4 (4)
Corporate bonds	14 (14)	Business-related participations	4 (4)
Emerging-market government bonds	4 (4)	Cash	7 (8)
ABS/MBS	3 (3)		

3-month reinvestment yield



Portfolio management

- Further expansion of illiquid investments
- Increase of equity exposure including derivatives due to rising stock markets
- Reinvestment yield benefits from investments in high-yield corporate bonds and emerging-market bonds

¹ Management view – not fully comparable with IFRS figures, e.g. including real estate in own use and cash. Fair values as at 31.3.2023 (31.12.2022).
² Developed markets. ³ Including derivatives: 3.3% (2.0%).

Investment result

€m	Q1 2023	Return ¹
Regular income	1,601	3.0%
Write-ups/write-downs	–28	–0.1%
Change in expected credit loss (ECL)	–38	–0.1%
Disposal gains/losses	166	0.3%
Fair-value change	74	0.1%
Other income/expenses	–164	–0.3%
Investment result	1,612	3.0%

Q1 2022	Return ¹
1,415	2.3%
–1,031	–1.7%
0	0.0%
936	1.5%
–926	–1.5%
–136	–0.2%
258	0.4%

	Fixed income	Equities	Other
Write-ups/write-downs	0	0	–28
Disposal gains/losses	–189	0	355
Fair-value change	–46	252	–131

Fixed income	Equities	Other
–698	–310	–22
409	506	20
–1,333	207	200



xijian / iStockphoto / Getty Images

02

ERGO

ERGO Life and Health Germany

Key messages



- Higher CSM compared to prior year leads to higher absolute release of CSM and accordingly a higher total technical result
- Net income (€41m) burdened by non-directly attributable expenses in life new book

Insurance revenue (gross)


€m

Q1 2022		2,360
Foreign exchange		-2
Divestments/investments		0
Organic change		204
Q1 2023		2,562

- Increase of insurance revenues from life, short- and long-term health insurance, and travel

Total technical result


€m



- Total technical result mainly reflects release of CSM and risk adjustment in life and long-term health
- Short-term business (PAA) contribution of €39m to total technical result

Contractual service margin (CSM)¹

€m



- Contribution from new contracts smaller than CSM release due to
 - Run-off of life back book
 - Strategic shift of new health business into short-term contracts (PAA)
- Increase of CSM mainly driven by operational changes in life

ERGO Property-casualty Germany

Key messages



- Strong total technical result driven by very low large losses and low acquisition costs due to seasonality of new business
- Very high net result also driven by investment result

Insurance revenue (gross)


€m

Q1 2022		953
Foreign exchange		-4
Divestments/investments		0
Organic change		168
Q1 2023		1,117

- High increase mainly driven by motor, legal protection, liability, and personal accident, expected to level out in the remainder of the year

Total technical result

€m




High total technical result and low combined ratio in Q1 2023 especially driven by

- Significantly lower-than-expected major man-made and nat cat losses
- Strong operating performance
- Low acquisition costs due to seasonality of new business for PAA business
- Discount effect in CR of ~4pp
- Q1 2022 significantly burdened by large losses

Combined ratio

%



Key messages



- Total technical result in P-C mainly burdened mainly by large losses in Poland
- Total technical result of L/H in line with expectation; CSM release dominated by Belgium Life and Health

Insurance revenue (gross)


€m

Q1 2022		1,292
Foreign exchange		-9
Divestments/investments		42
Organic change		38
Q1 2023		1,362

- Good organic growth in life and health
- Thai entity fully consolidated (€48m)
- Lower revenues from legal protection

Total technical result

€m




Combined ratio at Q1 of 95.4% (88.7%) impacted by:

- Large losses in Poland (intra-group reinsurance relief consolidated in IFRS; ~2pp)
- Elevated claims in legal protection
- Seasonality effect in Spain

Contractual service margin (CSM)¹

€m



- Increase mainly driven by operating changes, mostly from Belgian health business (inflation assumptions)
- CSM release in line with expectations



03

Reinsurance

Life and health reinsurance

Key messages



- Strong total technical result above pro-rata guidance
- Pleasing new business development, especially in North America

Insurance revenue (gross)


€m



- Decline in Continental Europe and Asia, partly offset by growing revenue in North America and UK

Total technical result


€m



- Release of CSM and RA in line with expectations
- FinMoRe business performing well, yet negative FX effects of ~€66m, reflected in the result from insurance-related financial instruments

Contractual service margin (CSM)¹

€m



- Decline caused by a shift from CSM to RA, still representing future profits
- CSM from new contracts exceeds release through P&L


Property-casualty reinsurance

Key messages



- Strong revenue growth of 13.1% vs. Q1 2022
- Combined ratio of 86.5% largely in line with guidance despite elevated major losses
- Normalised combined ratio (85.1%) better than guidance allows to use higher-than-expected discount benefit to cater for claims uncertainty in basic losses


Insurance revenue (gross)



- Proportional business: New business and primary rate increases more than compensate for non-renewed shares
- XL business: Significant growth in nat cat at increased prices
- Global Specialty Insurance: Substantial growth across all units


Total technical result

€m



Combined ratio

%



- Increased combined ratio driven by higher major loss ratio of 16.4% (Q1 2022: 11.1%)
- Earthquake in Turkey single biggest event ...
- ... contributing to elevated discounting effects in combined ratio of ~8pp...
- ... offset by prudent reflection of claims risks in basic loss ratio
- Release of loss component of -1.1% (Q1 2022: -3.2%)
- Pleasing normalised combined ratio of 85.1%


April renewals – Continued trend of profitable growth with sizeable improvements in terms and conditions




Price
change

Renewals 2019–2022

%



Volume
change



April renewals 2023¹

+4.7%

Optimistic about
July renewals

+11.1%

Well positioned for
further business growth

Higher risk-adjusted pricing

- Individual price changes by line of business at a stable portfolio composition amount to 3.9% – additional price increase of 0.8pp due to changed portfolio mix with a higher share of property XL business
- Conservative inflation and other loss-trend assumptions (e.g. nat cat modelling) fully reflected in risk-adjusted price change

Improved portfolio quality

- Material improvement in terms and conditions (e.g. hours clauses, exclusions and clearer coverage definitions) in addition to higher attachment points and distinct pricing of covered perils, making portfolio more robust, though not fully reflected in numbers
- Market discipline allows typical soft market features to be eliminated and many reinsurance programmes to be restructured favourably for reinsurers



shansekala / iStockphoto / Getty Images


04

Transition to IFRS 9/17

Net result

Outlook 2023 vs. FY 2022

€bn (after tax)



Reinsurance

FY 2022 Outlook 2023

Life and health:
Total technical result

€1.0bn

~€1.0bn

Unchanged guidance for 2023 vs. 2022 actual, including some elements of prudence

Property-casualty:
Combined ratio

83.2%

~86%

Outlook 2023 includes operating improvements vs. normalised combined ratio of 86.6% in 2022, but also prudent assumptions



Thorsten Henn / Getty Images

05

Outlook

Group

Insurance revenue (gross)
~ **€58bn**

Net result
~ **€4.0bn**

Return on investment
> **2.2%**

ERGO

Insurance revenue (gross)
~ **€19bn**

Net result
~ **€0.7bn**

Combined ratio
P-C Germany
~ **89%**

International
~ **90%**

Reinsurance

Insurance revenue (gross)
~ **€39bn**

Net result
~ **€3.3bn**

Combined ratio
Property-casualty
~ **86%**

Total technical result
Life and health
~ **€1.0bn**

This presentation contains forward-looking statements that are based on current assumptions and forecasts of the management of Munich Re. Known and unknown risks, uncertainties and other factors could lead to material differences between the forward-looking statements given here and the actual development, in particular of the results, financial situation and performance of our Group. Obvious fluctuations in the incidence of major losses in addition to the pronounced volatility of the capital markets and exchange rates – as well as the special features of IFRS accounting – make an accurate forecast of results impossible. The Group assumes no liability to update these forward-looking statements or to make them conform to future events or developments. Due to rounding, there may be minor deviations in summations and in the calculation of percentages in this presentation. Figures for FY 2022 are based on IFRS 17 and IAS 39 including overlay approach.